Payment overview · 2025
General Payments
$1,096.02
41 reported records · 20 companies
Healthcare provider profile · identity verified
Laura C. Dickerson, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology · GAINESVILLE, FL · NPI 1417031238
Verified facts
What the public records show
CMS Open Payments records show Laura C. Dickerson, MD received $1,096.02 in general payments during 2025 across 41 reported records.
GENZYME CORPORATION accounted for 16.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Imbruvica.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Imbruvica by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYNPARZA as an associated drug or biological on 9531 records involving 5030 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lynparza by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIQRAY as an associated drug or biological on 36 records involving 4 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Piqray by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $175.82 | 16.0% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $151.83 | 13.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $92.49 | 8.4% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $81.51 | 7.4% | 4 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $67.27 | 6.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $65.22 | 6.0% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $56.35 | 5.1% | 2 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $51.70 | 4.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.25 | 4.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.77 | 4.2% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $44.33 | 4.0% | 2 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $39.33 | 3.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $26.60 | 2.4% | 1 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $25.77 | 2.4% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.76 | 2.3% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $23.05 | 2.1% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.58 | 1.9% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $20.31 | 1.9% | 1 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $17.61 | 1.6% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $14.47 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,096.02 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $175.82 | 6 | 2025 |
Source payment records
|
|||||
| General - Interventional Oncology Normalized: general interventional oncology |
Device | Boston Scientific Corporation | $151.83 | 1 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $103.30 | 4 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $57.51 | 3 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $51.70 | 2 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $51.70 | 2 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $49.75 | 2 | 2025 |
Source payment records
|
|||||
| Padcev Normalized: padcev |
Drug | Astellas Pharma US Inc | $45.57 | 2 | 2025 |
Source payment records
|
|||||
| Zoladex Normalized: zoladex |
Drug | TerSera Therapeutics LLC | $39.33 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $29.84 | 2 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $26.22 | 1 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $26.22 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $26.22 | 1 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $25.77 | 1 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | Celgene Corporation | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| Afstyla Normalized: afstyla |
Biological | CSL Behring | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| Idelvion Normalized: idelvion |
Biological | CSL Behring | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| IMBRUVICA imbruvica |
2025 | Imbruvica | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LYNPARZA open payments reported associated product |
CMS Open Payments — General Payments 9531 supporting records · 5030 recipient NPIs · example record 1206131376 |
Lynparza · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 24 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 24 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PIQRAY open payments reported associated product |
CMS Open Payments — General Payments 36 supporting records · 4 recipient NPIs · example record 1200336082 |
Piqray · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 307 | 113 |
| Eliquis | Apixaban | 101 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 66 | 23 |
| Gabapentin | Gabapentin | 64 | 16 |
| Tamoxifen Citrate | Tamoxifen Citrate | 52 | 18 |
| Ondansetron Odt | Ondansetron | 51 | 39 |
| Revlimid | Lenalidomide | 46 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 44 | 11 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 43 | 35 |
| Dexamethasone | Dexamethasone | 38 | 15 |
| Hydroxyurea | Hydroxyurea | 38 | 16 |
| Levofloxacin | Levofloxacin | 38 | 35 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Letrozole | Letrozole | 32 | 13 |
| Verzenio | Abemaciclib | 31 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 29 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Imbruvica | Ibrutinib | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | 13 |
| Lynparza | Olaparib | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Piqray | Alpelisib | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Gleevec | Imatinib Mesylate | 13 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 12 | suppressed |
| Exemestane | Exemestane | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,096.02 · 41 records | GENZYME CORPORATION | ADCETRIS, AYVAKIT, Afstyla, ELAHERE, ENHERTU, EPKINLY, General - Interventional Oncology, IMBRUVICA, INQOVI, Idelvion, KISQALI, LONSURF, LUTATHERA, OCTAGAM IMMUNE GLOBULIN (HUMAN), OGSIVEO, OPDIVO, OPDUALAG, ORGOVYX, PYRUKYND, Padcev, TALZENNA, Trodelvy, Vyloy, XPOVIO, XTANDI, ZYNLONTA, Zoladex | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Imbruvica play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error